Sangamo Therapeutics Inc. (SGMO)
| Bid | 0.7 |
| Market Cap | 157.97M |
| Revenue (ttm) | 57.8M |
| Net Income (ttm) | -97.94M |
| EPS (ttm) | -0.49 |
| PE Ratio (ttm) | -1.43 |
| Forward PE | -2.07 |
| Analyst | Buy |
| Ask | 0.72 |
| Volume | 2,996,097 |
| Avg. Volume (20D) | 6,655,700 |
| Open | 0.70 |
| Previous Close | 0.69 |
| Day's Range | 0.67 - 0.71 |
| 52-Week Range | 0.30 - 3.18 |
| Beta | 1.58 |
About SGMO
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ...
Analyst Forecast
According to 6 analyst ratings, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 468.99% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call TranscriptSangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communication...
